Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993397 | 0.80 | CES1 (0.46) | CES2CES1CA1CA2LMNA | |
| SCHEMBL28464639 | 0.79 | ALDH1A1 (0.52) | CES2CES1GSK3BAKR1C3LMNA | |
| SCHEMBL5961932 | 0.79 | ALOX15 (0.52) | CES2CES1GSK3BCA1CA2 | |
| SCHEMBL17801512 | 0.78 | SMN1; SMN2 (0.50) | CYP1A2GSK3BHAO1LMNAALDH1A1 | |
| SCHEMBL1702960 | 0.77 | MEN1 (0.44) | CES2CES1CYP1A2GSK3BCA1 | |
| SCHEMBL28590990 | 0.75 | CA2 (0.50) | GSK3BCA1CA2LMNAALDH1A1 | |
| SCHEMBL2162369 | 0.75 | CES2 (0.53) | CES2CES1GSK3BCYP1B1MEN1 | |
| SCHEMBL28400743 | 0.75 | CA1 (0.57) | CES2CES1CYP1A2GSK3BCA1 | |
| SCHEMBL17542156 | 0.73 | ALDH1A1 (0.42) | CES2CES1CYP1A2GSK3BOGG1 | |
| SCHEMBL21836881 | 0.73 | RAB9A (0.39) | CES2CES1GSK3BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3636637-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | Forma Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20100197514-A1 | PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF | HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7687252-B2 | Protein crystal of human cytochrome P450 aromatase and uses thereof | Hauptman-Woodward Medcial Research Institute, Inc. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090204378-A1 | PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF | HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009061859-A2 | PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF | HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875848-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | CES2 353/4885CES1 49/4885CYP1A2 1824/4885 |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | CES2 353/4885CES1 49/4885CYP1A2 1824/4885 |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | CES2 353/4885CES1 49/4885CYP1A2 1824/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | CES2 353/4885CES1 49/4885CYP1A2 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.